Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Eli Lilly ( LLY 0.53%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of its ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon receptor (GCP) for obesity, observers are already making comparisons of the drug ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...